Arbutus Biopharma Corporation (0SGC.L)
| Chiusura precedente | 2,3380 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 2,17 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,7050 |
| Prossima data utili | 01 mar 2023 - 06 mar 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Financially strong with a projected cash runway into the second quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729, our RNAi therapeutic, and NA therapy On-track to achieve multiple additional milestones before year end Conference call and webcast today at 8:45 AM ET WARMINSTER, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveragin
- GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
WARMINSTER, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 11:30 am GMT / 6:30 am EDT. A live webcast of the presentation can b
- GlobeNewswire
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in combination with an RNAi, may provide enhanced HBV immune response Data to be presented as poster presentations Additional safety findings lead to discontinuation of AB-836 development Conference call and webcast scheduled for Friday, November 4th at 8:45 AM ET WARMINSTER, Pa., Nov. 01, 2022 (GLOBE N
